Results 81 to 90 of about 1,013 (109)

ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models

iScience
Summary: Hepatocellular carcinoma (HCC) currently lacks effective therapies, leaving a critical need for new treatment options. A previous study identified the anaplastic lymphoma kinase (ALK) amplification in HCC patients, raising the question of ...
Suresh Bugide, Dhana Sekhar Reddy, Parmanand Malvi, Romi Gupta, Narendra Wajapeyee   +4 more
doaj   +1 more source

The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib

npj Precision Oncology
Lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), effectively targets most single ALK mutations in ALK-positive non-small cell lung cancer (NSCLC), while acquired resistance remains a major clinical challenge.
Mai Nagasaka, Francesco Facchinetti, Ludovic Bigot, Floriane Brayé, Matthew R. Groves, Juvenal Yosa, Anthonie van der Wekken, Mihaela Aldea, Benjamin Besse, David Planchard, Charles Naltet, Ryohei Katayama, Ken André Olaussen, Yohann Loriot, Luc Friboulet   +14 more
doaj   +1 more source

Safety of Lorlatinib in Patients with Unresectable Advanced ALK-Positive Non-Small-Cell Lung Cancer Previously Treated with ALK Inhibitors: A Single-Arm, Open-Label, Phase IV Study in India

Indian Journal of Medical and Paediatric Oncology
Lorlatinib is approved in India for patients with previously treated anaplastic lymphoma kinase (ALK)–positive advanced or recurrent non-small-cell lung cancer (NSCLC).
Ullas Batra, Vineet G. Gupta, Nirmal Raut, Tushar Patil, Harsha Panchal, Nikhil Ghadyalpatil, Anand Pathak, Chirag Desai, Shailesh Bondarde, Minish Jain, Christian Russel Reyes, Shyam Parvatini, Seema Pai, Francesca Toffalorio, Holger Thurm, Bivas Biswas   +15 more
doaj   +1 more source

Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report

ALK gene rearrangements are detected in approximately 3% to 5% of NSCLC. ALK tyrosine kinase inhibitors, such as third-generation lorlatinib, have exhibited remarkable efficacy in ALK-rearranged NSCLC; however, they have been associated with a low ...
Rahul Ladwa, MPhil, William J. Mullally, MBBCh BAO, Kenneth J. O’Byrne, MD, James A. Fletcher, M.B.B.S.   +3 more
core   +1 more source

Conformation of the Macrocyclic Drug Lorlatinib in Polar and Nonpolar Environments : A MD Simulation and NMR Study

, 2019
The replica exchange molecular dynamics (REMD) simulation is demonstrated to readily predict the conformations of the macrocyclic drug lorlatinib, as validated by solution NMR studies.
Shi, Jiye, Poongavanam, Vasanthanathan, Zhu, Weiliang, Zhu, Weiliang,, Erdélyi, Máté,, Xu, Zhijian, Poongavanam, Vasanthanathan,, Shi, Jiye,, Erdélyi, Máté, Peng, Cheng, Atilaw, Yoseph, Wang, Jinan, Kihlberg, Jan, Peng, Cheng,, Wang, Jinan,, Atilaw, Yoseph,, Kihlberg, Jan,, Xu, Zhijian,   +17 more
core   +2 more sources

Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report

Case Reports in Oncology
Introduction: Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) are at increased risk of central nervous system (CNS) metastasis at initial diagnosis and throughout treatment.
Yutaka Fujiwara, Katsuhiro Masago, Reiko Matsuzawa, Teppei Yamaguchi, Naohiro Watanabe, Junichi Shimizu, Eiichi Sasaki, Yoshitsugu Horio   +7 more
doaj   +1 more source

A pragmatic guide for management of adverse events associated with lorlatinib

Lorlatinib is a brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) indicated for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
Grizzard, M, Felip, E, Bauer, TM, Ou, SHI, Mok, T, Liu, G, Goto, Y, Solomon, BJ, Stratmann, J, Mazieres, J   +9 more
core   +1 more source

Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison

Journal of Comparative Effectiveness Research
Aim: Lorlatinib demonstrated superior efficacy over alectinib as a first-line treatment for ALK-positive (ALK+) advanced/metastatic non-small cell lung cancer in a matching-adjusted indirect comparison (MAIC) using 3-year follow-up data from CROWN ...
Todd Bauer, Devin Abrahami, Anna Polli, Haitao Chu, Priya Ramachandran, Conor Chandler, Min Tan, James Truscott, Julien Mazieres, Christine A Garcia   +9 more
doaj   +1 more source

New findings on the incidence and management of CNS adverse reactions in ALK-positive NSCLC with lorlatinib treatment

Discover Oncology
To explore the presentation and control of CNS adverse reactions in patients with ALK-positive NSCLC treated with lorlatinib. This study includes a retrospective case report from Sir Run Run Shaw Hospital on a lorlatinib-treated patient with CNS adverse ...
Fanfan Chu, Wenxi Zhang, Hong Hu
doaj   +1 more source

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data

Frontiers in Oncology
IntroductionAnaplastic lymphoma kinase (ALK) inhibitors (ALKi) are the standard treatment for metastatic, ALK-positive non-small cell lung cancer (NSCLC).
Vera Damuzzo, Vera Damuzzo, Lorenzo Gasperoni, Luna Del Bono, Andrea Ossato, Andrea Ossato, Alessandro Inno, Andrea Messori, Andrea Messori   +8 more
doaj   +1 more source